Verbruggen B - Search Results

1

The type of factor VIII deficient plasma used influences the performance of the Nijmegen modification of the Bethesda assay for factor VIII inhibitors.

Verbruggen B, Giles A, Samis J, Verbeek K, Mensink E, Novákovà I. Verbruggen B, et al. Thromb Haemost. 2001 Dec;86(6):1435-9. Thromb Haemost. 2001. PMID: 11776311

2

The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability.

Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. Verbruggen B, et al. Thromb Haemost. 1995 Feb;73(2):247-51. Thromb Haemost. 1995. PMID: 7792738

3

Semi-automated detection of the factor V mutation by allele specific amplification and capillary electrophoresis.

van de Locht LT, Kuypers AW, Verbruggen BW, Linssen PC, Nováková IR, Mensink EJ. van de Locht LT, et al. Among authors: verbruggen bw. Thromb Haemost. 1995 Nov;74(5):1276-9. Thromb Haemost. 1995. PMID: 8607109

4

Factor VIIA determination compared to D-Dimer in diagnosis of deep venous thrombosis.

Janssen MC, Verbruggen BW, ter Hark PJ, Nováková IR. Janssen MC, et al. Among authors: verbruggen bw. Thromb Res. 1997 Jun 1;86(5):423-6. doi: 10.1016/s0049-3848(97)00088-1. Thromb Res. 1997. PMID: 9211634 Free article. No abstract available.

5

Homozygous cystathionine beta-synthase deficiency, combined with factor V Leiden or thermolabile methylenetetrahydrofolate reductase in the risk of venous thrombosis.

Kluijtmans LA, Boers GH, Verbruggen B, Trijbels FJ, Novakova IR, Blom HJ. Kluijtmans LA, et al. Among authors: verbruggen b. Blood. 1998 Mar 15;91(6):2015-8. Blood. 1998. PMID: 9490685 Free article.

6

A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis.

Giles AR, Verbruggen B, Rivard GE, Teitel J, Walker I. Giles AR, et al. Among authors: verbruggen b. Thromb Haemost. 1998 Apr;79(4):872-5. Thromb Haemost. 1998. PMID: 9569207

7

Rapid D-dimer assays to exclude deep venous thrombosis and pulmonary embolism: current status and new developments.

Janssen MC, Wollersheim H, Verbruggen B, Nováková IR. Janssen MC, et al. Among authors: verbruggen b. Semin Thromb Hemost. 1998;24(4):393-400. doi: 10.1055/s-2007-996028. Semin Thromb Hemost. 1998. PMID: 9763357 Review.

8

Meloxicam, 15 mg/day, spares platelet function in healthy volunteers.

de Meijer A, Vollaard H, de Metz M, Verbruggen B, Thomas C, Novakova I. de Meijer A, et al. Among authors: verbruggen b. Clin Pharmacol Ther. 1999 Oct;66(4):425-30. doi: 10.1053/cp.1999.v66.a101063. Clin Pharmacol Ther. 1999. PMID: 10546927 Clinical Trial.

9

Hyperhomocysteinemia and other thrombotic risk factors in women with placental vasculopathy.

van der Molen EF, Verbruggen B, Nováková I, Eskes TK, Monnens LA, Blom HJ. van der Molen EF, et al. Among authors: verbruggen b. BJOG. 2000 Jun;107(6):785-91. doi: 10.1111/j.1471-0528.2000.tb13341.x. BJOG. 2000. PMID: 10847236 Clinical Trial.

10

A 4% solution of bovine serum albumin may be used in place of factor VIII:C deficient plasma in the control sample in the Nijmegen Modification of the Bethesda factor VIII:C inhibitor assay.

Verbruggen B, van Heerde W, Novákovà I, Lillicrap D, Giles A. Verbruggen B, et al. Thromb Haemost. 2002 Aug;88(2):362-4. Thromb Haemost. 2002. PMID: 12195715 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

58 results

Search Page

Filters